Interview: Russian pharma needs to tap foreign markets to boost its development
This article was originally published in Scrip
The development of the national pharmaceutical industry was one of the hottest discussion points at Adam Smith Conferences' 15th Annual International Russian Pharmaceutical Forum in St Petersburg on May 19th-21st. Scrip's Maria Bailey asked Viktor Dmitriev, executive director of the Association of Russian Pharmaceutical Manufacturers (ARPhM), about the challenges which the industry faces.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.